查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1869578

迷幻藥市場：產業趨勢與全球預測 - 依物質來源、迷幻藥類型、目標適應症、給藥途徑和主要地區劃分

Psychedelic Drugs Market: Industry Trends and Global Forecasts - Distribution by Origin of Substance, Psychedelic Substance, Target Disease Indications, Route of Administration and Key Geographical Regions
出版日期: | 出版商: Roots Analysis | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格

全球迷幻藥市場：概論

根據 Roots Analysis 預測，全球迷幻藥市場在預測期內將以 15% 的複合年增長率增長，從目前的 31.9 億美元增長至 128.9 億美元。

市場規模和機會分析基於以下參數進行區隔：

物質來源

  • 天然來源
  • 合成來源

羥基類型

  • γ-羥基丁酸迷幻劑
  • 氯胺酮
  • 搖頭丸
  • 裸蓋菇素

適應症

  • 憂鬱症與焦慮症
  • 疼痛障礙
  • 睡眠相關障礙
  • 創傷

給藥途徑

  • 口服
  • 靜脈注射
  • 鼻內給藥
  • 舌下給藥

主要地區

  • 北美
  • 歐洲
  • 亞太地區
  • 世界其他地區

全球迷幻藥市場：成長與趨勢

精神病性疾患是指使用致幻物質（特別是致幻劑誘發的感知障礙）後出現持續性感知障礙的精神健康問題。 （HPPD）。 HPPD表現為持續的視覺現象，例如視覺噪音、殘像和運動感知改變，這些現象並非由其他精神或生理疾病引起，且會造成顯著的痛苦。

據預測，精神病性障礙與其他心理健康問題疊加，每年將導致全球生產力損失超過1兆美元。近期數據顯示，新冠疫情加劇了現有趨勢，尤其是在年輕女性族群中，自新冠疫情爆發以來，青少年發病率成長速度加快了130%，年輕成年人發病率成長速度加快了57%。截至2022年，抗憂鬱藥物是處方藥中第三常用類別。世界衛生組織指出，有效治療憂鬱症和其他精神疾病面臨許多障礙，包括對這些疾病缺乏了解、持續存在的社會歧視、誤診以及缺乏有效的治療方法。鑑於這些挑戰，臨床研究正日益關注迷幻化合物在治療憂鬱症和其他精神疾病的潛力。研究人員認為，在適當劑量下使用迷幻藥可能有助於緩解患者的某些嚴重心理症狀。

迷幻化合物已被證實能夠影響多種神經傳導物質系統，包括與血清素、乙醯膽鹼、正腎上腺素和多巴胺相關的系統。目前，製藥業的眾多利害關係人正在研究迷幻化合物的天然和合成衍生物。預計未來十年，迷幻藥市場將迎來顯著成長。

全球迷幻藥市場：關鍵洞察

本報告深入分析了全球迷幻藥市場的現狀，並指出了該行業的潛在成長機會。報告的主要發現包括：

  • 目前，全球有超過45家公司聲稱正在開發和評估基於多種迷幻化合物（包括氯胺酮和裸蓋菇素）的候選治療藥物。
迷幻藥市場-IMG1
  • 研發管線包括基於多種迷幻藥類別的候選產品，這些產品正針對多種目標疾病適應症進行研究，並具有多種給藥途徑。
  • 儘管有濫用風險，但裸蓋菇素（33%）仍是一類具有高治療價值的重要化合物，多家公司正在探索其在主流醫學中的應用。
  • 大多數迷幻藥（60%）設計用於口服，但也有一些候選藥物有用於鼻內和靜脈給藥的製劑。
  • 從全球視角來看，隨著世界各地的聯邦和地方監管機構逐漸認識到這類產品的臨床意義，預計未來幾年該行業將取得顯著發展。
  • 鑑於迷幻藥這一新興領域的巨大潛力，多家機構已授予超過500項資助，總額超過2.75億美元。
  • （在美國）該領域的利害關係人獲得資助數量以5%的複合年增長率增長，其中超過45%的資助金額是透過R01機制授予的。
  • 美國國立衛生研究院（NIH）下屬的多個資助機構都參與了該領域的研究。在所有參與的部門中，美國國家心理健康研究所（NIMH）、美國國家藥物濫用研究所（NIDA）、美國國家普通醫學科學研究所（NIGMS）和美國國家酒精濫用與酒精中毒研究所（NIAAA）的參與尤為突出。
  • 詞雲圖展示了研究機構在這個新興領域的研究興趣，特別關注憂鬱症和創傷後壓力症候群 (PTSD) 等疾病。
  • 近年來，針對多種迷幻化合物治療各種疾病的臨床試驗已陸續進行。
  • 這種日益增長的興趣也體現在合作活動中，涵蓋不同藥物類別的各類合作協議已在多個地區簽署。
迷幻藥市場-IMG2
  • 大多數合作都集中在裸蓋菇素 (psilocybin) 的研發上 (42%)，其次是氯胺酮 (ketamine) (19%)。事實上，首個氯胺酮類似物 SPRAVATO 已獲準用於治療難治性憂鬱症。
  • 多項涉及關鍵產業利害關係人的交易聚焦於物質使用疾患和神經系統疾病（例如重度憂鬱症和創傷後壓力症候群）的潛在療法。
  • 北美公司目前正積極透過策略性收購來加強其在當地的影響力，這些交易的主要價值推動因素包括產品組合的擴展和地理的擴張。
  • 一些隸屬於知名大學的傑出科學家積極參與基於迷幻劑的干預療法的臨床開發活動，並已成為該領域的關鍵意見領袖。
  • 未來市場規模的預測是基於已上市和處於後期研發階段的迷幻劑療法的銷售額，這些療法涵蓋各個治療領域和主要地區。
迷幻藥市場-IMG3
  • 事實上，業內專家證實了該領域的巨大潛力。整體機會廣泛分佈於各種天然和合成物質以及給藥途徑。

全球迷幻藥市場：主要區隔市場

依目標疾病劃分，市場分為憂鬱症和焦慮症、疼痛障礙、睡眠相關障礙和創傷。目前，創傷區隔市場在迷幻藥市場中佔主導地位，佔市場佔有率的大部分。

依地區劃分，市場分為北美、歐洲、亞太地區及世界其他地區。目前，北美在迷幻藥市場佔主導地位，收入佔有率最大。

全球迷幻藥市場代表性公司

  • Celon Pharma
  • iX Biopharma
  • MAPS Public Benefit
  • MindMed
  • Janssen Pharmaceuticals
  • Jazz Pharmaceutical

目錄

第一章：前言

第二章：摘要整理

第三章：導論

  • 章節概要
  • 迷幻藥的歷史
  • 迷幻藥的潛在治療應用
  • 關於醫療用途、毒性問題以及採購相關挑戰和認知​​的法規
  • 未來展望機遇

第四章 市場概況：迷幻藥

  • 章節概述
  • 迷幻藥：已上市及在研產品線
  • 迷幻藥：開發商列表

第四章：總部分析

第五章：公司簡介

  • 章節概述
  • Celon Pharma
  • iX Biopharma
  • MAPS Public Benefit
  • MindMed
  • Janssen Pharmaceuticals
  • Jazz Pharmaceutical

第六章：臨床試驗分析

  • 章節概述
  • 範圍與方法
  • 迷幻藥治療學：臨床試驗分析

    第七章：臨床試驗中心分析

第八章：關鍵意見領袖分析

第九章：學術資助分析

第十章：合作與夥伴關係

第十一章：併購

第十二章：市場預測與機會分析

第十三章：結論

第十四章：高階主管見解

第十五章：附錄一：表格資料

第十六章：附錄二：公司與機構列表

Product Code: RA100209

Global Psychedelic Drugs Market: Overview

As per Roots Analysis, the global psychedelic drugs market is expected to grow from USD 3.19 billion in the current year to USD 12.89 billion, at a CAGR of 15% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Origin of Substance

  • Natural
  • Synthetic

Type of Psychedelic Substance

  • Gamma-hydroxybutyrate
  • Ketamine
  • MDMA
  • Psilocybin

Target Disease Indications

  • Depression and Anxiety Disorders
  • Pain Disorders
  • Sleep Related Disorders
  • Trauma

Route of Administration

  • Oral
  • Intravenous
  • Intranasal
  • Sublingual

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Global Psychedelic Drugs Market: Growth and Trends

Psychedelic disorders are mental health issues defined by persistent perceptual disturbances following the use of psychedelic substances, especially hallucinogen persisting perception disorder (HPPD). HPPD involves persistent visual phenomena such as visual snow, trails, and altered motion perception, which are not part of another mental or medical condition and cause significant distress.

Psychedelic disorders, in addition to other mental health issues, are projected to lead to worldwide productivity losses surpassing USD 1 trillion each year. Recent data suggests that the pandemic intensified existing trends, especially among younger women, with rates rising 130% quicker for teenagers and 57% quicker for young adults after the COVID-19 pandemic. As of 2022, antidepressants ranked as the third most prevalent category of prescribed medications. The WHO states that there are numerous obstacles for effectively treating depression and other mental health disorders including insufficient understanding of these conditions, ongoing social stigma, incorrect diagnoses, and limited effective treatments. Due to such difficulties, an increase in clinical research emphasizes the treatment possibilities of psychedelic compounds for mental health issues such as depression. Researchers suggest that when given in suitable doses, psychedelics may assist in alleviating certain severe psychological effects in patients.

Psychedelic compounds have been shown to affect multiple neurotransmitter systems, including those related to serotonin, acetylcholine, norepinephrine, and dopamine. At present, various participants in the pharmaceutical sector are involved in research of both natural and synthetic derivatives of psychedelic compounds. The market for psychedelic drugs is expected to experience significant growth in the next decade.

Global Psychedelic Drugs Market: Key Insights

The report delves into the current state of global psychedelic drugs market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • More than 45 players from across the world presently claim to be engaged in the development and evaluation of therapeutic candidates based on a number of psychedelic compounds, such as ketamine and psilocybin.
Psychedelic Drugs Market - IMG1
  • The pipeline features product candidates based on a variety of psychedelic drug classes, which are being investigated for a wide range of target disease indications and have different routes of administration.
  • Despite its potential for misuse, psilocybin (33%) is an important class of chemical compounds with substantial therapeutic value; several companies are engaged in exploring its use in mainstream healthcare.
  • Majority (60%) of the psychedelic therapeutics are designed for oral administration; there are certain candidates that are available in formulations that are intended for intranasal and intravenous dosing.
  • From a global perspective, this industry is anticipated to evolve significantly over the next few years as federal / regional regulators in different nations are gradually convinced of the clinical significance of this product class.
  • Several organizations, having realized the untapped opportunity within this emerging segment of psychedelic therapeutics, have awarded grants of over USD 275 million across 500+ instances.
  • The number of grants awarded to stakeholders in this domain (in the US) has increased at a CAGR of 5%; more than 45% of the total amount was awarded under the R01 mechanism.
  • The field has witnessed the involvement of various sponsor institutes from within the NIH; of all the involved departments, the participation of the NIMH, NIDA, NIGMS, and NIAAA was observed to be relatively more prominent.
  • The word cloud represents the area of interest of research organizations within this emerging domain; indications such as depression and posttraumatic stress disorder have garnered significant attention.
  • Several trials evaluating various psychedelic compounds against a wide range of therapeutic indications have been registered in the recent past.
  • The growing interest is also reflected in the partnership activity; a number of different types of deals involving various drug classes have been established across multiple geographies.
Psychedelic Drugs Market - IMG2
  • Majority of the partnerships were focused on development of psilocybin (42%), followed by ketamine (19%). In fact, the first ketamine analogue, SPRAVATO, was approved for treatment of resistant depression.
  • A number of deals that involved key industry stakeholders were focused on therapy candidates for substance use disorders and neurological conditions, such as major depressive disorder and posttraumatic stress disorder.
  • Presently, North American companies are actively consolidating their indigenous presence through strategic acquisitions; key value drivers behind such deals include both portfolio and geographical expansion.
  • A number of eminent scientists from renowned universities have emerged as key opinion leaders in this domain, owing to their active involvement in clinical development efforts related to interventions based on psychedelics.
  • Future market size, based on revenue reported from the sales of marketed and late-stage psychedelic-based therapies, is anticipated to be distributed across different therapeutic areas and key geographical regions.
Psychedelic Drugs Market - IMG3
  • In fact, opinions from industry experts confirm the vast potential of this segment; the overall opportunity is well distributed across the various natural / synthetically derived substances and routes of administration.

Global Psychedelic Drugs Market: Key Segments

Trauma Segment Occupies the Largest Share of the Psychedelic Drugs Market

In terms of target disease indications, the market is segmented into depression and anxiety disorders, pain disorders, sleep related disorders and trauma. Currently, the trauma segment dominates the psychedelic drug market, capturing majority share of the market.

North America Accounts for the Largest Share of the Market

In terms of key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. Currently, North America dominates the psychedelic drugs market and accounts for the largest revenue share.

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

  • Founder & Chief Executive Officer, Small Company
  • Chief Operating Officer and Chief Medical Officer, Mid-sized Company
  • Chief Operating Officer, Small Company
  • Chief Communications Officer, Mid-sized Company
  • Associate Research Scientist, Large Company

Example Players in the Global Psychedelic Drugs Market

  • Celon Pharma
  • iX Biopharma
  • MAPS Public Benefit
  • MindMed
  • Janssen Pharmaceuticals
  • Jazz Pharmaceutical

Global Psychedelic Drugs Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global psychedelic drugs market, focusing on key market segments, including [A] origin of substance, [B] type of psychedelic substance [C] target disease indications, [D] route of administration and [H] key geographical regions.
  • Market Landscape: A comprehensive evaluation of marketed / pipeline molecules, considering various parameters, such as [A] phase of development of lead candidates, [B] type of psychedelic substance, [C] origin of psychedelic substance, [D] target therapeutic area (s), [E] route of administration and [F] dosing frequency. Additionally, a comprehensive evaluation of drug developer(s), based on [A] year of their establishment, [B] company size, and [C] location of headquarters.
  • Company Profiles: In-depth profiles of companies that are engaged in the development of at least two or more psychedelic-based therapies, focusing on [A] company overview, [B] financial information (if available), [C] product portfolio, and [E] recent developments and an informed future outlook.
  • Clinical Trial Analysis: An in-depth analysis of completed, ongoing and planned clinical studies of various psychedelic therapeutics, highlighting prevalent trends across various relevant parameters, such as [A] trial registration year, [B] phase of development, [C] current trial status, [D] enrolled patient population, [E] geographical distribution of trials, [F] study design, [G] leading industry, [H] study focus, [I] target therapeutic area and [J] key geographical regions.
  • Clinical Trial Site Analysis: A detailed analysis of clinical trial sites where the studies have been / are being conducted for evaluation of various psychedelic therapeutics, based on relevant parameters, such as [A] type of psychedelic substance, [B] trial phase, [C] target disease indications and [D] location of the trial.
  • Grant Analysis: An insightful analysis of nearly 550 grants that were awarded to research institutes engaged in psychedelic therapeutics related projects, based on the parameters, such as the [A] year of grant award, [B] amount awarded, [C] funding institute center, [D] support period, [E] type of grant application, [F] purpose of grant award, [G] activity code, [H] responsible study section, [I] prominent program officers and [J] type of recipient organizations.
  • Partnerships and Collaborations: A comprehensive analysis of various collaborations and partnerships that have been inked amongst stakeholders in this domain, based on [A] year of partnership, [B] type of partnership and [C] regional activity.
  • Mergers and Acquisitions: A detailed analysis of the various mergers and acquisitions that have taken place in this domain, based on parameters, such as [A] key value drivers, [B] year of acquisition, [C] type of acquisition, [D] geographical location of the acquirer and [E] the acquired company.

Key Questions Answered in this Report

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
    • 1.2.1. Research Assumptions
    • 1.2.2. Project Methodology
    • 1.2.3. Forecast Methodology
    • 1.2.4. Robust Quality Control
    • 1.2.5. Key Considerations
      • 1.2.5.1. Demographics
      • 1.2.5.2. Economic Factors
      • 1.2.5.3. Government Regulations
      • 1.2.5.4. Supply Chain
      • 1.2.5.5. COVID Impact / Related Factors
      • 1.2.5.6. Market Access
      • 1.2.5.7. Healthcare Policies
      • 1.2.5.8. Industry Consolidation
  • 1.3 Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. History of Psychedelic Substances
  • 3.3. Potential Therapeutic Applications of Psychedelic Substances
  • 3.4. Regulation, Toxicity Concerns, Procurement-related Challenges and Perceptions Regarding Medical Use
  • 3.5. Future Opportunities

4. MARKET LANDSCAPE: PSYCHEDELIC THERAPEUTICS

  • 4.1. Chapter Overview
  • 4.2. Psychedelic Therapeutics: Marketed and Development Pipeline
    • 4.2.1. Analysis by Phase of Development
    • 4.2.2. Analysis by Type of Psychedelic Substance
    • 4.2.3. Analysis by Origin of Psychedelic Substance
    • 4.2.4. Analysis by Target Therapeutic Area
    • 4.2.5. Analysis by Route of Administration
    • 4.2.6. Analysis by Dosing Frequency
  • 4.3. Psychedelic Therapeutics: List of Developers
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size

4. 3.3. Analysis by Location of Headquarters

  • 4.4. Grid Analysis: Distribution by Phase of Development, Origin of Psychedelic Substance and Location of Headquarters

5. COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. Celon Pharma
    • 5.2.1. Company Overview
    • 5.2.2. Financial Information
    • 5.2.3. Psychedelic Therapeutics Portfolio
      • 5.2.3.1. Esketamine DPI
    • 5.2.4. Recent Developments and Future Outlook
  • 5.3. iX Biopharma
    • 5.3.1. Company Overview
    • 5.3.2. Financial Information
    • 5.3.3. Psychedelic Therapeutics Portfolio
      • 5.3.3.1. Wafermine(TM)
      • 5.3.3.2. Unnamed (Ketamine)
    • 5.3.4. Recent Developments and Future Outlook
  • 5.4. MAPS Public Benefit
    • 5.4.1. Company Overview
    • 5.4.2. Financial Information
    • 5.4.3. Psychedelic Therapeutics Portfolio
      • 5.4.3.1. Unnamed (MDMA)
      • 5.4.3.2. Unnamed (Ibogaine Hydrochloride)
      • 5.4.3.3. Unnamed (LSD)
      • 5.4.3.4. Unnamed (Ayahuasca)
    • 5.4.4. Recent Developments and Future Outlook
  • 5.5. MindMed
    • 5.5.1. Company Overview
    • 5.5.2. Psychedelic Therapeutics Portfolio
      • 5.5.2.1. LSD Micro-dosing
      • 5.5.2.2. 18-MC
      • 5.5.2.3. Unnamed (LSD and MDMA)
    • 5.5.3. Recent Developments and Future Outlook
  • 5.6. Janssen Pharmaceuticals
    • 5.6.1. Company Overview
    • 5.6.2. Financial Information
    • 5.6.3. Psychedelic Therapeutics Portfolio
      • 5.6.3.1. SPRAVATO(R)
    • 5.6.4. Recent Developments and Future Outlook
  • 5.7. Jazz Pharmaceutical
    • 5.7.1. Company Overview
    • 5.7.2. Financial Information
    • 5.7.3. Psychedelic Therapeutics Portfolio
      • 5.7.3.1. XYREM(R)
      • 5.7.3.2. JZP-258
      • 5.7.3.3. JZP-324
    • 5.7.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Scope and Methodology
  • 6.3. Psychedelic Therapeutics: Clinical Trial Analysis
    • 6.3.1. Analysis by Trial Registration Year
    • 6.3.2. Analysis by Trial Phase
    • 6.3.3. Analysis by Trial Recruitment Status
    • 6.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
    • 6.3.5. Analysis by Study Design
    • 6.3.6. Leading Trial Sponsors: Analysis by Number of Registered Trials
    • 6.3.7. Leading Industry Sponsors: Analysis by Number of Registered Trials
    • 6.3.8. Word Cloud: Key Focus Areas
    • 6.3.9. Analysis by Target Therapeutic Area
    • 6.3.10. Popular Interventions: Analysis by Number of Registered Trials
    • 6.3.11. Geographical Analysis by Number of Registered Trials
    • 6.3.12. Geographical Analysis by Trial Recruitment Status
    • 6.3.13. Geographical Analysis by Number of Patients Enrolled

7. CLINICAL TRIAL SITE ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Psychedelic Therapeutics: Clinical Trial Site Analysis
    • 7.3.1. Analysis by Type of Psychedelic Substance
    • 7.3.2. Analysis by Trial Phase
    • 7.3.3. Analysis by Target Therapeutic Area
    • 7.3.4. Analysis by Location of Clinical Trial Site

8. KEY OPINION LEADER (KOL) ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Assumptions and Methodology
  • 8.3. Principal Investigators Involved in Clinical Trials
    • 8.3.1. Analysis by Type of Organization (KOL Affiliation)
    • 8.3.2. Geographical Distribution of KOLs
  • 8.4. Prominent KOLs
  • 8.5. KOL Benchmarking: Roots Analysis' Assessment versus Third Party (ResearchGate Score)
  • 8.6. Most Active KOLs
    • 8.6.1. KOL Profile: A (Emory School of Medicine)
    • 8.6.2. KOL Profile: B (Imperial College London)
    • 8.6.3. KOL Profile: C (Rigshospitalet)
    • 8.6.4. KOL Profile: D (Thriving Mind South Florida)
    • 8.6.5. KOL Profile: E (University Health Network)

9. ACADEMIC GRANTS ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Psychedelic Therapeutics: Analysis of Academic Grants
    • 9.3.1. Analysis by Year of Grant Award
    • 9.3.2. Analysis by Amount Awarded
    • 9.3.3. Analysis by Funding Institute Center
    • 9.3.4. Analysis by Support Period
    • 9.3.5. Analysis by Funding Institute Center and Support Period
    • 9.3.6. Analysis by Type of Grant Application
    • 9.3.7. Analysis by Purpose of Grant Award
    • 9.3.8. Analysis by Activity Code
    • 9.3.9. Analysis by Study Section Involved
    • 9.3.10. Analysis by Recipient Organization
    • 9.3.11. Geographical Distribution of Recipient Organizations
    • 9.3.12. Word Cloud: Emerging Focus Areas
    • 9.3.13. Popular Psychedelic Therapeutics: Analysis by Number of Grants
    • 9.3.14. Popular Funding Institute Centers: Analysis by Number of Grants
    • 9.3.15. Prominent Program Officers: Analysis by Number of Grants
    • 9.3.16. Popular Recipient Organizations: Analysis by Number of Grants

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Chapter Overview
  • 10.2. Partnership Models
  • 10.3. Psychedelic Therapeutics: List of Partnerships and Collaborations
    • 10.3.1. Analysis by Year of Partnership
    • 10.3.2. Analysis by Type of Partnership
    • 10.3.3. Analysis by Type of Partnership and Type of Psychedelic Substance Involved
    • 10.3.4. Analysis by Type of Partnership and Phase of Development of Involved Intervention
    • 10.3.5. Analysis by Type of Partnership and Target Therapeutic Area Mentioned
    • 10.3.6. Analysis by Type of Psychedelic Substance and Target Therapeutic Area
    • 10.3.7. Analysis by Type of Partnership and Type of Partner
    • 10.3.8. Analysis by Type of Psychedelic Substance Involved and Type of Partner
    • 10.3.9. Most Active Players: Analysis by Number of Partnerships
    • 10.3.10. Regional Analysis
      • 10.3.10.1 Intercontinental and Intracontinental Agreements

11. MERGERS AND ACQUISITIONS

  • 11.1. Chapter Overview
  • 11.2. Acquisition Models
  • 11.3. Psychedelic Therapeutics: Mergers and Acquisitions
    • 11.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
    • 11.3.2. Analysis by Type of Acquisition
    • 11.3.3. Analysis by Type of Psychedelic Substance Involved
    • 11.3.4. Analysis by Year of Acquisition and Type of Psychedelic Substance Involved
    • 11.3.5. Most Active Players: Analysis by Number of Acquisitions
    • 11.3.6. Regional Analysis
      • 11.3.6.1. Continent-Wise Distribution of Acquisitions
      • 11.3.6.2. Country-Wise Distribution of Acquisitions
    • 11.3.7. Analysis by Key Value Drivers
      • 11.3.7.1, Analysis by Year of Acquisition and Key Value Drivers

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Forecast Methodology and Assumptions
  • 12.3. Global Psychedelic Therapeutics Market
  • 12.4. Global Psychedelic Therapeutics Market: Individual Product Sales Forecasts
    • 12.4.1. COMP360 (COMPASS Pathways)
      • 12.4.1.1. Target Patient Population
      • 12.4.1.2. Sales Forecast
    • 12.4.2. Esketamine DPI (Celon Pharma)
      • 12.4.2.1. Target Patient Population
      • 12.4.2.2. Sales Forecast
    • 12.4.3. FT218 (Avadel Pharmaceuticals)
      • 12.4.3.1. Target Patient Population
      • 12.4.3.2. Sales Forecast
    • 12.4.4. JZP-258 (Jazz Pharmaceuticals)
      • 12.4.4.1. Target Patient Population
      • 12.4.4.2. Sales Forecast
    • 12.4.5. NRX-100 (NeuroRx)
      • 12.4.5.1. Target Patient Population
      • 12.4.5.2. Sales Forecast
    • 12.4.6. R-107 (Doughlas pharmaceuticals)
      • 12.4.6.1. Target Patient Population
      • 12.4.6.2. Sales Forecast
    • 12.4.7. SPRAVATO(R) (Janssen Pharmaceuticals)
      • 12.4.7.1. Target Patient Population
      • 12.4.7.2. Sales Forecast
    • 12.4.8. Unnamed (MDMA) (MAPS Public Benefit)
      • 12.4.8.1. Target Patient Population
      • 12.4.8.2. Sales Forecast
    • 12.4.9. Unnamed (Psilocybin) (The Emmes Company)
      • 12.4.9.1. Target Patient Population
      • 12.4.9.2. Sales Forecast
    • 12.4.10. Wafermine(TM) (iX Biopharma)
      • 12.4.10.1. Target Patient Population
      • 12.4.10.2. Sales Forecast
    • 12.4.11. XYREM(R) (Jazz Pharmaceuticals)
      • 12.4.11.1. Target Patient Population
      • 12.4.11.2. Sales Forecast
  • 12.5. Global Psychedelic Therapeutics Market: Distribution by Origin of Psychedelic Substance, Till 2035
    • 12.5.1. Global Psychedelic Therapeutics Market for Synthetic Substances, Till 2035
    • 12.5.2. Global Psychedelic Therapeutics Market for Natural Substances, Till 2035
  • 12.6. Global Psychedelic Therapeutics Market: Distribution by Type of Psychedelic Substance, Till 2035
    • 12.6.1. Global Psychedelic Therapeutics Market for GHB, Till 2035
    • 12.6.2. Global Psychedelic Therapeutics Market for Ketamine, Till 2035
    • 12.6.3. Global Psychedelic Therapeutics Market for MDMA, Till 2035
    • 12.6.4. Global Psychedelic Therapeutics Market for Psilocybin, Till 2035
  • 12.7. Global Psychedelic Therapeutics Market: Distribution by Geography, Till 2035
    • 12.7.1. Psychedelic Therapeutics Market in North America, Till 2035
    • 12.7.2. Psychedelic Therapeutics Market in Europe, Till 2035
    • 12.7.3. Psychedelic Therapeutics Market in Asia-Pacific and Rest of the World, Till 2035
  • 12.8. Psychedelic Therapeutics Market: Distribution by Target Therapeutic Area, Till 2035
    • 12.8.1. Global Psychedelic Therapeutics Market for Depression and Anxiety Disorders, Till 2035
    • 12.8.2. Global Psychedelic Therapeutics Market for Pain Disorders, Till 2035
    • 12.8.3. Global Psychedelic Therapeutics Market for Sleep-Related Disorders, Till 2035
    • 12.8.4. Global Psychedelic Therapeutics Market for Trauma, Till 2035
  • 12.9. Global Psychedelic Therapeutics Market: Distribution by Route of Administration, Till 2035
    • 12.9.1. Global Psychedelic Therapeutics Market for Intranasal Therapies, Till 2035
    • 12.9.2. Global Psychedelic Therapeutics Market for Intravenous Therapies, Till 2035
    • 12.9.3. Global Psychedelic Therapeutics Market for Oral Therapies, Till 2035
    • 12.9.4. Global Psychedelic Therapeutics Market for Sublingual Therapies, Till 2035

13. CONCLUDING REMARKS

  • 13.1. Chapter Overview
  • 13.2. Key Takeaways

14. EXECUTIVE INSIGHTS

  • 14.1. Chapter Overview
  • 14.2 Company A
    • 14.2.1. Company Snapshot
    • 14.2.2. Interview Transcript: Founder & Chief Executive Officer
  • 14.3. Company B
    • 14.3.1. Company Snapshot
    • 14.3.2. Interview Transcript: Founder & Chief Executive Officer
  • 14.4. Company C
    • 14.4.1. Company Snapshot
    • 14.4.2. Interview Transcript: Chief Operating Officer and Chief Medical Officer
  • 14.5 Company D
    • 14.5.1. Company Snapshot
    • 14.5.2. Interview Transcript: Chief Operating Officer
  • 14.6 Company E
    • 14.6.1. Company Snapshot
    • 14.6.2. Interview Transcript: Chief Communications Officer
  • 14.7 Company F
    • 14.7.1. Company Snapshot
    • 14.7.2. Interview Transcript: Assistant Professor of Psychiatry

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 4.1. Psychedelic Therapeutics: Marketed and Development Pipeline
  • Table 4.2. Psychedelic Therapeutics: List of Developers
  • Table 5.1. Psychedelic Therapeutics: List of Companies Profiled
  • Table 5.2. Celon Pharma: Company Snapshot
  • Table 5.3. Drug Profile: Esketamine DPI
  • Table 5.4. Celon Pharma: Recent Developments and Future Outlook
  • Table 5.5. iX Biopharma: Company Snapshot
  • Table 5.6. Drug Profile: Wafermine(R)
  • Table 5.7. Drug Profile: Unnamed (Ketamine)
  • Table 5.8. iX Biopharm: Recent Developments and Future Outlook
  • Table 5.9. MAPS Public Benefit: Company Snapshot
  • Table 5.10. Drug Profile: Unnamed (MDMA)
  • Table 5.11. Drug Profile: Unnamed Ibogaine Hydrochloride
  • Table 5.12. Drug Profile: Unnamed (LSD)
  • Table 5.13. Drug Profile: Unnamed (Ayahuasca)
  • Table 5.14. MAPS Public Benefit: Recent Developments and Future Outlook
  • Table 5.15. MindMed: Company Snapshot
  • Table 5.16. Drug Profile: LSD Micro-Dosing
  • Table 5.17. Drug Profile: 18-MC
  • Table 5.18. MindMed: Recent Developments and Future Outlook
  • Table 5.19. Janssen Pharmaceutical: Company Snapshot
  • Table 5.20. Drug Profile: SPRAVATO(R)
  • Table 5.21. Janssen Pharmaceutical: Recent Developments and Future Outlook
  • Table 5.22. Jazz Pharmaceutical: Company Snapshot
  • Table 5.23. Drug Profile: XYREM(R)
  • Table 5.24. Drug Profile: JZP-258
  • Table 5.25. Drug Profile: JZP-324
  • Table 5.26. Jazz pharmaceutical: Recent Developments and Future Outlook
  • Table 7.1. Psychedelic Therapeutics: List of Principal Investigators
  • Table 7.2. KOLs: Roots Analysis Proprietary Scoring System
  • Table 7.3. KOL Profile: A (Emory School of Medicine)
  • Table 7.4. KOL Profile: B (Imperial College London)
  • Table 7.5. KOL Profile: C (Rigshospitalet)
  • Table 7.6. KOL Profile: D (Thriving Mind South Florida)
  • Table 7.7. KOL Profile: E (University Health Network)
  • Table 10.1. Psychedelic Therapeutics: List of Partnerships and Collaborations
  • Table 11.1. Psychedelic Therapeutics: List of Mergers and Acquisition
  • Table 11.2. Psychedelic Therapeutics: Key Growth Drivers
  • Table.15.1. Psychedelic Therapeutics: Distribution by Phase of Development
  • Table.15.2. Psychedelic Therapeutics: Distribution by Type of Psychedelic Substance
  • Table.15.3. Psychedelic Therapeutics: Distribution by Origin of Psychedelic Substance
  • Table.15.4. Psychedelic Therapeutics: Distribution by Target Therapeutic Area
  • Table.15.5. Psychedelic Therapeutics: Distribution by Route of Administration
  • Table.15.6. Psychedelic Therapeutics: Distribution by Dosing Frequency
  • Table.15.7. Psychedelic Therapeutics Developers: Distribution by Year of Establishment
  • Table.15.8. Psychedelic Therapeutics Developers: Distribution by Company Size
  • Table.15.9. Celon Pharma: Annual Revenues, Since 2016 (PLN Million)
  • Table.15.10. iX Biopharma: Annual Revenues, Since 2015 (USD Million)
  • Table.15.11. MAPS Public Benefit: Annual Revenues, Since 2016 (USD Million)
  • Table.15.12. Janssen Pharmaceuticals: Annual Revenues, Since 2016 (USD Million)
  • Table.15.13. Jazz Pharmaceutical: Annual Revenues, Since 2015 (USD Million)
  • Table.15.14. Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year
  • Table.15.15. Clinical Trial Analysis: Distribution by Trial Phase
  • Table.15.16. Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Table.15.17. Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
  • Table.15.18. Clinical Trial Analysis: Distribution by Study Design
  • Table.15.19. Leading Trial Sponsors: Distribution by Number of Registered Trials
  • Table.15.20. Leading Industry Sponsors: Distribution by Number of Registered Trials
  • Table.15.21. Clinical Trial Analysis: Distribution by Target Therapeutic Area
  • Table.15.22. Popular Interventions: Distribution by Number of Registered Trials
  • Table.15.23. Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
  • Table.15.24. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
  • Table.15.25. Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
  • Table.15.26. Clinical Trial Site Analysis: Cumulative Distribution of Clinical Trial Centre
  • Table.15.27. Clinical Trial Site Analysis: Distribution by Type of Psychedelic Substance
  • Table.15.28. Clinical Trial Site Analysis: Distribution by Trial Phase
  • Table.15.29. Clinical Trial Site Analysis: Distribution by Target Therapeutic Area
  • Table.15.30. Clinical Trial Site Analysis: Distribution by Location of Clinical Trial Center
  • Table.15.31. KOL Analysis: Distribution by Type of Organization (KOL Affiliation)
  • Table.15.32. KOL Analysis: Distribution by Location of Organization (KOL Affiliation)
  • Table.15.33. KOL Analysis: Leading Organizations (KOL Affiliation)
  • Table.15.34. KOL Benchmarking: Roots Analysis' Assessment versus Third Party (ResearchGate Score)
  • Table.15.35. KOL Analysis: Most Prominent KOLs
  • Table.15.36. Grant Analysis: Cumulative Trend by Year of Grant Award, Since 2015
  • Table.15.37. Grant Analysis: Cumulative Distribution by Amount Awarded, Since 2015 (USD Million)
  • Table.15.38. Grant Analysis: Distribution by Funding Institute Center
  • Table.15.39. Grant Analysis: Distribution by Support Period
  • Table.15.40. Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Table.15.41. Grant Analysis: Distribution by Type of Grant Application
  • Table.15.42. Grant Analysis: Distribution by Purpose of Grant Award
  • Table.15.43. Grant Analysis: Distribution by Activity Code
  • Table.15.44. Grant Analysis: Distribution by Study Section Involved
  • Table.15.45. Grant Analysis: Distribution by Recipient Organization
  • Table.15.46. Word Cloud Analysis: Emerging Focus Areas
  • Table.15.47. Popular Psychedelic Therapeutics: Distribution by Number of Grants
  • Table.15.48. Popular Funding Institute Centers: Distribution by Number of Grants
  • Table.15.49. Grant Analysis: Prominent Program Officers
  • Table.15.50. Popular Recipient Organizations: Distribution by Number of Grants
  • Table.15.51. Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2017
  • Table.15.52. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table.15.53. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Psychedelic Substance Involved
  • Table.15.54. Partnerships and Collaborations: Distribution by Type of Partnership and Phase of Development of Involved Intervention
  • Table.15.55. Partnerships and Collaborations: Distribution by Type of Psychedelic Substance and Target Therapeutic Area
  • Table.15.56. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table.15.57. Partnerships and Collaborations: Distribution by Type of Psychedelic Substance Involved and Type of Partner
  • Table.15.58. Most Active Players: Distribution by Number of Partnerships
  • Table.15.59. Partnership and Collaborations: Regional Distribution
  • Table.15.60. Mergers and Acquisitions: Cumulative Year-wise Trend, Since 2017
  • Table.15.61. Mergers and Acquisitions: Distribution by Type of Acquisition
  • Table.15.62. Mergers and Acquisitions: Distribution by Type of Psychedelic Substance Involved
  • Table.15.63. Mergers and Acquisitions: Distribution by Year of Acquisition and Type of Psychedelic Substance Involved
  • Table.15.64. Most Active Players: Distribution by Number of Acquisition
  • Table.15.65. Mergers and Acquisitions: Regional Distribution
  • Table.15.66. Mergers and Acquisitions: Distribution by Key Value Drivers
  • Table.15.67. Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
  • Table.15.68. Global Psychedelic Therapeutics Market, Till 2035 (USD Million)
  • Table.15.69. COMP360 (COMPASS Pathways): Sales Forecast
  • Table.15.70. Esketamine DPI (Celon Pharma): Sales Forecast
  • Table.15.71. FT218 (Avadel Pharmaceuticals): Sales Forecast
  • Table.15.72. JZP-258 (Jazz Pharmaceuticals): Sales Forecast
  • Table.15.73. NRX-100 (NeuroRx): Sales Forecast
  • Table.15.74. R-107 (Doughlas pharmaceuticals): Sales Forecast
  • Table.15.75. SPRAVATO(R) (Janssen Pharmaceuticals): Sales Forecast
  • Table.15.76. Unnamed (MDMA) (MAPS Public Benefit): Sales Forecast
  • Table.15.77. Unnamed (Psilocybin) (The Emmes Company): Sales Forecast
  • Table.15.78. Wafermine(TM) (iX Biopharma): Sales Forecast
  • Table.15.79. XYREM(R) (Jazz Pharmaceuticals): Sales Forecast
  • Table.15.80. Global Psychedelic Therapeutics Market: Distribution by Origin of Psychedelic Substances, Till 2035 (USD Million)
  • Table.15.81. Global Psychedelic Therapeutics Market for Synthetic Substances, Till 2035 (USD Million)
  • Table.15.82. Global Psychedelic Therapeutics Market for Natural Substances, Till 2035 (USD Million)
  • Table.15.83. Global Psychedelic Therapeutics Market: Distribution by Type of Psychedelic Substance, Till 2035 (USD Million)
  • Table.15.84. Global Psychedelic Therapeutics Market for GHB, Till 2035 (USD Million)
  • Table.15.85. Global Psychedelic Therapeutics Market for Ketamine, Till 2035 (USD Million)
  • Table.15.86. Global Psychedelic Therapeutics Market for MDMA, Till 2035 (USD Million)
  • Table.15.87. Global Psychedelic Therapeutics Market for Psilocybin, Till 2035 (USD Million)
  • Table.15.88. Global Psychedelic Therapeutics Market: Distribution by Geography, Till 2035 (USD Million)
  • Table.15.89. Global Psychedelic Therapeutics Market in North America, Till 2035 (USD Million)
  • Table.15.90. Global Psychedelic Therapeutics Market in Europe, Till 2035 (USD Million)
  • Table.15.91. Global Psychedelic Therapeutics Market in Asia Pacific and Rest of the World, Till 2035 (USD Million)
  • Table.15.92. Psychedelic Therapeutics Market: Distribution by Target Therapeutic Area, Till 2035 (USD Million)
  • Table.15.93. Global Psychedelic Therapeutics Market for Depression and Anxiety Disorders, Till 2035 (USD Million)
  • Table.15.94. Global Psychedelic Therapeutics Market for Pain Disorders, Till 2035 (USD Million)
  • Table.15.95. Global Psychedelic Therapeutics Market for Sleep-Related Disorders, Till 2035 (USD Million)
  • Table.15.96. Global Psychedelic Therapeutics Market for Trauma, Till 2035 (USD Million)
  • Table.15.97. Global Psychedelic Therapeutics Market: Distribution by Route of Administration, Till 2035 (USD Million)
  • Table.15.98. Global Psychedelic Therapeutics Market for Intranasal Therapies, Till 2035 (USD Million)

List of Figures

  • Figure 3.1. Historical Evolution of Psychedelics
  • Figure 3.2. Psychedelic Substances: Potential Therapeutic Areas
  • Figure 3.3. Classification of Psychedelic Substances under the Federal Controlled Substances Act
  • Figure 3.4. Psychedelic Therapeutics: Status of Legalization / Decriminalization Across Different Geographies
  • Figure 3.5. Psychedelic Therapeutics: Toxicity Comparison of Different Substances
  • Figure 4.1. Psychedelic Therapeutics: Distribution by Phase of Development
  • Figure 4.2. Psychedelic Therapeutics: Distribution by Type of Psychedelic Substance
  • Figure 4.3. Psychedelic Therapeutics: Distribution by Origin of Psychedelic Substance
  • Figure 4.4. Psychedelic Therapeutics: Distribution by Target Therapeutic Area
  • Figure 4.5. Psychedelic Therapeutics: Distribution by Route of Administration
  • Figure 4.6. Psychedelic Therapeutics: Distribution by Dosing Frequency
  • Figure 4.7. Psychedelic Therapeutics Developers: Distribution by Year of Establishment
  • Figure 4.8. Psychedelic Therapeutics Developers: Distribution by Company Size
  • Figure 4.9. Psychedelic Therapeutics Developers: Distribution by Location of Headquarters
  • Figure 4.10. Grid Representation: Distribution by Phase of Development, Origin of Psychedelic Substance and Location of Headquarters
  • Figure 5.1. Celon Pharma: Annual Revenues, Since 2016 (PLN Million)
  • Figure 5.2. iX Biopharma: Annual Revenues, Since 2015 (USD Million)
  • Figure 5.3. MAPS Public Benefit: Annual Revenues, Since 2016 (USD Million)
  • Figure 5.4. Janssen Pharmaceuticals: Annual Revenues, Since 2016 (USD Million)
  • Figure 5.5. Jazz Pharmaceutical: Annual Revenues, Since 2015 (USD Million)
  • Figure 6.1. Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year
  • Figure 6.2. Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 6.3. Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Figure 6.4. Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
  • Figure 6.5. Clinical Trial Analysis: Distribution by Study Design
  • Figure 6.6. Leading Trial Sponsors: Distribution by Number of Registered Trials
  • Figure 6.7. Leading Industry Sponsors: Distribution by Number of Registered Trials
  • Figure 6.8. Word Cloud: Key Focus Areas
  • Figure 6.9. Clinical Trial Analysis: Distribution by Target Therapeutic Area
  • Figure 6.10. Popular Interventions: Distribution by Number of Registered Trials
  • Figure 6.11. Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
  • Figure 6.12. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
  • Figure 6.13. Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
  • Figure 7.1. Clinical Trial Site Analysis: Cumulative Distribution of Clinical Trial Centre
  • Figure 7.2. Clinical Trial Site Analysis: Distribution by Type of Psychedelic Substance
  • Figure 7.3. Clinical Trial Site Analysis: Distribution by Trial Phase
  • Figure 7.4. Clinical Trial Site Analysis: Distribution by Target Therapeutic Area
  • Figure 7.5. Clinical Trial Site Analysis: Distribution by Location of Clinical Trial Center
  • Figure 8.1. KOL Analysis: Distribution by Type of Organization (KOL Affiliation)
  • Figure 8.2. KOL Analysis: Geographical Distribution of KOLs in America
  • Figure 8.3. KOL Analysis: Geographical Distribution of KOLs in Europe, Asia-Pacific and RoW
  • Figure 8.4. KOL Analysis: Distribution by Location of Organization (KOL Affiliation)
  • Figure 8.5. KOL Analysis: Leading Organizations (KOL Affiliation)
  • Figure 8.6. KOL Analysis: Dot-Plot of KOLs
  • Figure 8.7. KOL Benchmarking: Roots Analysis' Assessment versus Third Party (ResearchGate Score)
  • Figure 8.8. KOL Analysis: Most Prominent KOLs
  • Figure 9.1. Grant Analysis: Cumulative Trend by Year of Grant Award, Since 2015
  • Figure 9.2. Grant Analysis: Cumulative Distribution by Amount Awarded, Since 2015 (USD Million)
  • Figure 9.3. Grant Analysis: Distribution by Funding Institute Center
  • Figure 9.4. Grant Analysis: Distribution by Support Period
  • Figure 9.5. Grant Analysis: Distribution by Funding Institute Center and Support Period
  • Figure 9.6. Grant Analysis: Distribution by Type of Grant Application
  • Figure 9.7. Grant Analysis: Distribution by Purpose of Grant Award
  • Figure 9.8. Grant Analysis: Distribution by Activity Code
  • Figure 9.9. Grant Analysis: Distribution by Study Section Involved
  • Figure 9.10. Grant Analysis: Distribution by Recipient Organization
  • Figure 9.11. Grant Analysis: Regional Distribution of Recipient Organizations
  • Figure 9.12. Word Cloud Analysis: Emerging Focus Areas
  • Figure 9.13. Popular Psychedelic Therapeutics: Distribution by Number of Grants
  • Figure 9.14. Popular Funding Institute Centers: Distribution by Number of Grants
  • Figure 9.15. Grant Analysis: Prominent Program Officers
  • Figure 9.16. Popular Recipient Organizations: Distribution by Number of Grants
  • Figure 10.1. Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2017
  • Figure 10.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Psychedelic Substance Involved
  • Figure 10.4. Partnerships and Collaborations: Distribution by Type of Partnership and Phase of Development of Involved Intervention
  • Figure 10.5. Partnerships and Collaborations: Distribution by Type of Psychedelic Substance and Target Therapeutic Area
  • Figure 10.6. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 10.7. Partnerships and Collaborations: Distribution by Type of Psychedelic Substance Involved and Type of Partner
  • Figure 10.8. Most Active Players: Distribution by Number of Partnerships
  • Figure 10.9. Partnership and Collaborations: Regional Distribution
  • Figure 10.10. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 11.1. Mergers and Acquisitions: Cumulative Year-wise Trend, Since 2017
  • Figure 11.2. Mergers and Acquisitions: Distribution by Type of Acquisition
  • Figure 11.3. Mergers and Acquisitions: Distribution by Type of Psychedelic Substance Involved
  • Figure 11.4. Mergers and Acquisitions: Distribution by Year of Acquisition and Type of Psychedelic Substance Involved
  • Figure 11.5. Most Active Players: Distribution by Number of Acquisition
  • Figure 11.6. Mergers and Acquisitions: Regional Distribution
  • Figure 11.7. Mergers and Acquisitions: Intercontinental and Intracontinental Deals
  • Figure 11.8. Mergers and Acquisitions: Distribution by Key Value Drivers
  • Figure 11.9. Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
  • Figure 12.1. Global Psychedelic Therapeutics Market, Till 2035 (USD Million)
  • Figure 12.2. COMP360 (COMPASS Pathways): Target Patient Population
  • Figure 12.3. COMP360 (COMPASS Pathways): Sales Forecast
  • Figure 12.4. Esketamine DPI (Celon Pharma): Target Patient Population
  • Figure 12.5. Esketamine DPI (Celon Pharma): Sales Forecast
  • Figure 12.6. FT218 (Avadel Pharmaceuticals): Target Patient Population
  • Figure 12.7. FT218 (Avadel Pharmaceuticals): Sales Forecast
  • Figure 12.8. JZP-258 (Jazz Pharmaceuticals): Target Patient Population
  • Figure 12.9. JZP-258 (Jazz Pharmaceuticals): Sales Forecast
  • Figure 12.10. NRX-100 (NeuroRx): Target Patient Population
  • Figure 12.11. NRX-100 (NeuroRx): Sales Forecast
  • Figure 12.12. R-107 (Doughlas pharmaceuticals): Target Patient Population
  • Figure 12.13. R-107 (Doughlas pharmaceuticals): Sales Forecast
  • Figure 12.14. SPRAVATO(R) (Janssen Pharmaceuticals): Target Patient Population
  • Figure 12.15. SPRAVATO(R) (Janssen Pharmaceuticals): Sales Forecast
  • Figure 12.16. Unnamed (MDMA) (MAPS Public Benefit): Target Patient Population
  • Figure 12.17. Unnamed (MDMA) (MAPS Public Benefit): Sales Forecast
  • Figure 12.18. Unnamed (Psilocybin) (The Emmes Company): Target Patient Population
  • Figure 12.19. Unnamed (Psilocybin) (The Emmes Company): Sales Forecast
  • Figure 12.20. Wafermine(TM) (iX Biopharma): Target Patient Population
  • Figure 12.21. Wafermine(TM) (iX Biopharma): Sales Forecast
  • Figure 12.22. XYREM(R) (Jazz Pharmaceuticals): Target Patient Population
  • Figure 12.23. XYREM(R) (Jazz Pharmaceuticals): Sales Forecast
  • Figure 12.24. Global Psychedelic Therapeutics Market: Distribution by Origin of Psychedelic Substances, Till 2035 (USD Million)
  • Figure 12.25. Global Psychedelic Therapeutics Market for Synthetic Substances, Till 2035
  • Figure 12.26. Global Psychedelic Therapeutics Market for Natural Substances, Till 2035
  • Figure 12.27. Global Psychedelic Therapeutics Market: Distribution by Type of Psychedelic Substance, Till 2035 (USD Million)
  • Figure 12.28. Global Psychedelic Therapeutics Market for GHB, Till 2035
  • Figure 12.29. Global Psychedelic Therapeutics Market for Ketamine, Till 2035
  • Figure 12.30. Global Psychedelic Therapeutics Market for MDMA, Till 2035
  • Figure 12.31. Global Psychedelic Therapeutics Market for Psilocybin, Till 2035
  • Figure 12.32. Global Psychedelic Therapeutics Market: Distribution by Geography, Till 2035 (USD Million)
  • Figure 12.33. Global Psychedelic Therapeutics Market in North America, Till 2035 (USD Million)
  • Figure 12.34. Global Psychedelic Therapeutics Market in Europe, Till 2035 (USD Million)
  • Figure 12.35. Global Psychedelic Therapeutics Market in Asia Pacific and Rest of the World, Till 2035 (USD Million)
  • Figure 12.36. Psychedelic Therapeutics Market: Distribution by Target Therapeutic Area, Till 2035 (USD Million)
  • Figure 12.37. Global Psychedelic Therapeutics Market for Depression and Anxiety Disorders, Till 2035 (USD Million)
  • Figure 12.38. Global Psychedelic Therapeutics Market for Pain Disorders, Till 2035 (USD Million)
  • Figure 12.39. Global Psychedelic Therapeutics Market for Sleep-Related Disorders, Till 2035 (USD Million)
  • Figure 12.40. Global Psychedelic Therapeutics Market for Trauma, Till 2035 (USD Million)
  • Figure 12.41. Global Psychedelic Therapeutics Market: Distribution by Route of Administration, Till 2035 (USD Million)
  • Figure 12.42. Global Psychedelic Therapeutics Market for Intranasal Therapies, Till 2035 (USD Million)
  • Figure 12.43. Global Psychedelic Therapeutics Market for Intravenous Therapies, Till 2035 (USD Million)
  • Figure 12.44. Global Psychedelic Therapeutics Market for Oral Therapies, Till 2035 (USD Million)
  • Figure 12.45. Global Psychedelic Therapeutics Market for Sublingual Therapies, Till 2035 (USD Million)